News | April 03, 2026
Merck secures landmark EU nod for KEYTRUDA in hard-to-treat ovarian cancer
Its a major breakthrough for women’s ovarian cancer care in Europe
Its a major breakthrough for women’s ovarian cancer care in Europe
The trial, dubbed MALBEC, marks the first in a broader late-phase development push for MK-8748, with a second NVAMD study expected to begin later this year
The acquisition brings two commercialized, differentiated medicines—EMPAVELI and SYFOVRE —to Biogen’s growth portfolio
Enthral.ai’s platform integrates AI-driven capabilities with compliance-first architecture, enabling automated training workflows
The company has achieved a turnover of around Rs 100 crore in FY 2025–26 and aims to achieve a turnover of Rs 500 crore in next three years
The approval is backed by results from Lilly’s ATTAIN clinical trial program, which showed significant weight loss among participants
The move represents a significant milestone in Lupin’s strategy to expand its specialty care portfolio and strengthen its presence in Europe
The company now offers the complete range of Apomorphine Hydrochloride in different fill volumes
Lonza will take on technology transfer, process optimization, and cGMP manufacturing, leveraging its global network and expertise in highly potent compounds
The program, which has been active for over a decade, will now expand its reach, focusing on equitable access to education, resources, and community-driven solutions for patients and care partners
Subscribe To Our Newsletter & Stay Updated
